Combination of bone marrow stromal cell transplantation with mobilization by granulocyte-colony stimulating factor promotes functional recovery after spinal cord transection

Jie Luo; Hong-tian Zhang; Xiao-dan Jiang; Shan Xue; Yi-quan Ke
November 2009
Acta Neurochirurgica;Nov2009, Vol. 151 Issue 11, p1483
Academic Journal
Spinal cord injury (SCI) results in severe neurological deficit. However, the functional recovery following SCI is very poor due to the neural lost and limited axonal regeneration. To date, there was no effective treatment. Recent studies have shown that bone marrow stromal cells (BMSCs) transplantated into the central nervous system (CNS) can survive and differentiate into neuronal-like cells. Additionally, granulocyte colony-stimulating factor (G-CSF) can mobilize hematopoietic stem cells and inhibit neural cell apoptosis. Thus, we aimed to evaluate the combined effect of BMSC transplantation and G-CSF administration on rats with traverse spinal cord injury. BMSCs were cultured in vitro, labeled with Hoechst33342, and then transplanted into the lesion site with or without G-CSF administration (50 μg/kg/day) for 5 subsequent days. The groups included an untreated control, along with treatment by G-CSF alone, BMSCs alone, and G-CSF + BMSCs. In this study, by the end of eighth week after SCI injury, the animals in group treated with G-CSF + BMSCs showed higher BBB scores than the other two groups. Morphometric assessment showed that the lesion areas in the rats of the G-CSF + BMSCs group were much smaller. Compared with the control, BMSC, and G-CSF groups, less expression of apoptosis cells and more neural-cell markers around the spinal cord injury were found in rats treated with G-CSF + BMSCs. The animals with the combination treatment achieved a better functional and morphologic recovery, although partial. This synergistic effect between BMSCs and G-CSF may be attributed to extrinsic and endogenous neurogenesis in the traverse spinal cord injury.


Related Articles

  • Prediction of duration and success rate of unrelated hematopoietic stem cell donor searches based on the patient's HLA-DRB1 allele and DRB1-DQB1 haplotype frequencies. Hirv, K.; Bloch, K.; Fischer, M.; Einsiedler, B.; Schrezenmeier, H.; Mytilineos, J. // Bone Marrow Transplantation;Oct2009, Vol. 44 Issue 7, p433 

    Rapid identification of a matched unrelated donor is essential for patients in need of hematopoietic SCT. We carried out a retrospective evaluation of 549 unrelated donor searches (UDSs), which were completed in 2005 for 23 German transplant centers. On the basis of the patient's HLA-DRB1 allele...

  • 23. Selected Aspects.  // Bone Marrow Transplantation;3/2/2002 Supplement, Vol. 29 Issue 5, pS237 

    Bone Marrow Transplantation (2001) 29, Suppl. 2, S237–S240. DOI: 10.1038/sj/bmt/1703492

  • A cross-sectional study on vision-related quality of life in patients with ocular GvHD. Pezzotta, S; Rossi, G C; Scudeller, L; Antoniazzi, E; Bianchi, P E; Perotti, C; Del Fante, C // Bone Marrow Transplantation;Sep2015, Vol. 50 Issue 9, p1224 

    Ocular GvHD affects about 40-60% of patients receiving bone marrow transplantation. Ocular complaints worsen quality of life (QoL), which, besides survival time, is a primary end point in a patient's follow-up. The aim of our study was to assess the ocular surface status and vision-related QoL...

  • Blood and marrow transplantation and nutritional support.  // Supportive Care in Cancer;May2010, Vol. 18 Issue 0, p57 

    Introduction Undernourishment on hospital admission has been considered as risk factor for complications and increased relapse/nonrelapse mortality in hematopoietic stem cell transplantation (HSCT) patients. Materials and methods All patients undergoing HSCT are at an increased risk for...

  • Hematopoietic stem cell transplantation in Lebanon: first comprehensive report. Bazarbachi, A.; Hatoum, H. A.; Mugharbel, A.; Otrock, Z. K.; Yassine, N.; Muwakkit, S.; Salem, Z.; Shebbo, W.; Jisr, T.; Abboud, M.; Ibrahim, A. // Bone Marrow Transplantation;Aug2008 Supplement, Vol. 42, pS96 

    Hematopoietic SCT (HSCT) has become a curative therapeutic strategy for several malignant and nonmalignant diseases. We report the comprehensive results of the first 10 years of experience in HSCT from the two major BMT units in Lebanon: Makassed University Hospital and the American University...

  • Application of Mesenchymal Stromal Cells in Bone Marrow Transplantation for Sensitized Recipients. Xu, Lu-Hong; Fang, Jian-Pei; Hong, Dong-Ling; Wu, Yan-Feng // Acta Haematologica;2012, Vol. 127 Issue 2, p105 

    Sensitized patients are at high risk for graft rejection during transplantation. It is of interest to investigate the effect of mesenchymal stromal cells (MSCs) in sensitized hematopoietic stem cell transplantation. MSCs were generated from bone marrow cells of BALB/c mice. The molecular markers...

  • Neurological Complications after Allogeneic Transplantation – Can We Do Better? Dowling, Mark R.; Ballen, Karen K. // Acta Haematologica;2019, Vol. 142 Issue 4, p193 

    Neurological complications remain a devastating and feared complication after hematopoietic cell transplantation, and a significant source of morbidity and mortality. Significantly, the development of neurologic complications portended a poorer prognosis, with increased non-relapsed mortality,...

  • The influence of cyclosporin alone, or cyclosporin and methotrexate, on the incidence of mixed haematopoietic chimaerism following allogeneic sibling bone marrow transplantation for severe aplastic anaemia. McCann, S.; Passweg, J.; Bacigalupo, A.; Locasciulli, A.; Locatelli, F.; Ryan, J.; Schrezenmeier, H.; Lawler, M. // Bone Marrow Transplantation;Jan2007, Vol. 39 Issue 2, p109 

    We previously reported a randomized trial comparing Cyclosporin-A (CsA) and short-term methotrexate versus CsA alone for graft-versus-host disease (GvHD) prophylaxis in 71 patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) from a human leucocyte antigen-identical...

  • Viral purging of haematological autografts: should we sneeze on the graft? Thirukkumaran, C. M.; Russell, J. A.; Stewart, D. A.; Morris, D. G. // Bone Marrow Transplantation;Jul2007, Vol. 40 Issue 1, p1 

    High-dose cytotoxic chemotherapy followed by autologous haematopoietic stem cell transplantation (ASCT) is extensively used for the treatment of many haematopoietic, as well as several epithelial cancers. Disease relapse may be the result of tumour contamination within autograft as evidenced by...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics